The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials
<i>Background and Objectives</i>: Substance use disorders (SUDs) affect millions worldwide. Despite increasing drug use, treatment options remain limited. Psychedelic-assisted therapy (PAT), integrating psychedelic substances with psychotherapy, offers a promising alternative by addressi...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/61/2/278 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849718518016114688 |
|---|---|
| author | Lavinia Hogea Dana Cătălina Tabugan Iuliana Costea Oana Albai Laura Nussbaum Adriana Cojocaru Leonardo Corsaro Teodora Anghel |
| author_facet | Lavinia Hogea Dana Cătălina Tabugan Iuliana Costea Oana Albai Laura Nussbaum Adriana Cojocaru Leonardo Corsaro Teodora Anghel |
| author_sort | Lavinia Hogea |
| collection | DOAJ |
| description | <i>Background and Objectives</i>: Substance use disorders (SUDs) affect millions worldwide. Despite increasing drug use, treatment options remain limited. Psychedelic-assisted therapy (PAT), integrating psychedelic substances with psychotherapy, offers a promising alternative by addressing underlying neural mechanisms. <i>Materials and Methods</i>: This review’s purpose is to investigate the current understanding of psychedelic therapy for treating SUDs, including tobacco, alcohol, and drug addiction. The systematic review approach focused on clinical trials and randomized controlled trials conducted from 2013 to 2023. The search was performed using PubMed, Google Scholar, and Consensus AI, following PRISMA guidelines. Studies involving psychedelics like LSD, psilocybin, ibogaine, and ayahuasca for treating various addictions were included, excluding naturalistic studies and reviews. <i>Results</i>: Our results highlight the key findings from 16 clinical trials investigating psychedelic therapy for SUDs. Psychedelics like psilocybin and ayahuasca showed promise in reducing alcohol and tobacco dependence, with psilocybin being particularly effective in decreasing cravings and promoting long-term abstinence. The studies revealed significant improvements in substance use reduction, especially when combined with psychotherapy. However, the variability in dosages and study design calls for more standardized approaches. These findings emphasize the potential of psychedelics in SUD treatment, though further large-scale research is needed to validate these results and develop consistent protocols. <i>Conclusions</i>: This research reviewed the past decade’s international experience, emphasizing the growing potential of psychedelic therapy in treating SUDs pertaining to alcohol, tobacco, and cocaine dependence. Psychedelics such as psilocybin and ketamine can reduce cravings and promote psychological well-being, especially when combined with psychotherapy. However, regulatory barriers and specialized clinical training are necessary to integrate these therapies into mainstream addiction treatment safely. Psychedelics offer a promising alternative for those unresponsive to conventional methods. |
| format | Article |
| id | doaj-art-d423098e396f4539b04a55d557eb8ed3 |
| institution | DOAJ |
| issn | 1010-660X 1648-9144 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj-art-d423098e396f4539b04a55d557eb8ed32025-08-20T03:12:22ZengMDPI AGMedicina1010-660X1648-91442025-02-0161227810.3390/medicina61020278The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical TrialsLavinia Hogea0Dana Cătălina Tabugan1Iuliana Costea2Oana Albai3Laura Nussbaum4Adriana Cojocaru5Leonardo Corsaro6Teodora Anghel7Neuroscience Department, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, RomaniaNeuroscience Department, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, RomaniaPsychology Department, West Univerity of Timisoara, 300223 Timisoara, RomaniaInternal Medicine Department, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, RomaniaNeuroscience Department, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, RomaniaNeuroscience Department, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, RomaniaCampus Bio Medico, 00128 Roma, ItalyNeuroscience Department, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania<i>Background and Objectives</i>: Substance use disorders (SUDs) affect millions worldwide. Despite increasing drug use, treatment options remain limited. Psychedelic-assisted therapy (PAT), integrating psychedelic substances with psychotherapy, offers a promising alternative by addressing underlying neural mechanisms. <i>Materials and Methods</i>: This review’s purpose is to investigate the current understanding of psychedelic therapy for treating SUDs, including tobacco, alcohol, and drug addiction. The systematic review approach focused on clinical trials and randomized controlled trials conducted from 2013 to 2023. The search was performed using PubMed, Google Scholar, and Consensus AI, following PRISMA guidelines. Studies involving psychedelics like LSD, psilocybin, ibogaine, and ayahuasca for treating various addictions were included, excluding naturalistic studies and reviews. <i>Results</i>: Our results highlight the key findings from 16 clinical trials investigating psychedelic therapy for SUDs. Psychedelics like psilocybin and ayahuasca showed promise in reducing alcohol and tobacco dependence, with psilocybin being particularly effective in decreasing cravings and promoting long-term abstinence. The studies revealed significant improvements in substance use reduction, especially when combined with psychotherapy. However, the variability in dosages and study design calls for more standardized approaches. These findings emphasize the potential of psychedelics in SUD treatment, though further large-scale research is needed to validate these results and develop consistent protocols. <i>Conclusions</i>: This research reviewed the past decade’s international experience, emphasizing the growing potential of psychedelic therapy in treating SUDs pertaining to alcohol, tobacco, and cocaine dependence. Psychedelics such as psilocybin and ketamine can reduce cravings and promote psychological well-being, especially when combined with psychotherapy. However, regulatory barriers and specialized clinical training are necessary to integrate these therapies into mainstream addiction treatment safely. Psychedelics offer a promising alternative for those unresponsive to conventional methods.https://www.mdpi.com/1648-9144/61/2/278psychedelic-assisted therapyaddiction treatmentdrug–psychotherapy combinationlysergic acid diethylamideMDMApsilocybin |
| spellingShingle | Lavinia Hogea Dana Cătălina Tabugan Iuliana Costea Oana Albai Laura Nussbaum Adriana Cojocaru Leonardo Corsaro Teodora Anghel The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials Medicina psychedelic-assisted therapy addiction treatment drug–psychotherapy combination lysergic acid diethylamide MDMA psilocybin |
| title | The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials |
| title_full | The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials |
| title_fullStr | The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials |
| title_full_unstemmed | The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials |
| title_short | The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials |
| title_sort | therapeutic potential of psychedelics in treating substance use disorders a review of clinical trials |
| topic | psychedelic-assisted therapy addiction treatment drug–psychotherapy combination lysergic acid diethylamide MDMA psilocybin |
| url | https://www.mdpi.com/1648-9144/61/2/278 |
| work_keys_str_mv | AT laviniahogea thetherapeuticpotentialofpsychedelicsintreatingsubstanceusedisordersareviewofclinicaltrials AT danacatalinatabugan thetherapeuticpotentialofpsychedelicsintreatingsubstanceusedisordersareviewofclinicaltrials AT iulianacostea thetherapeuticpotentialofpsychedelicsintreatingsubstanceusedisordersareviewofclinicaltrials AT oanaalbai thetherapeuticpotentialofpsychedelicsintreatingsubstanceusedisordersareviewofclinicaltrials AT lauranussbaum thetherapeuticpotentialofpsychedelicsintreatingsubstanceusedisordersareviewofclinicaltrials AT adrianacojocaru thetherapeuticpotentialofpsychedelicsintreatingsubstanceusedisordersareviewofclinicaltrials AT leonardocorsaro thetherapeuticpotentialofpsychedelicsintreatingsubstanceusedisordersareviewofclinicaltrials AT teodoraanghel thetherapeuticpotentialofpsychedelicsintreatingsubstanceusedisordersareviewofclinicaltrials AT laviniahogea therapeuticpotentialofpsychedelicsintreatingsubstanceusedisordersareviewofclinicaltrials AT danacatalinatabugan therapeuticpotentialofpsychedelicsintreatingsubstanceusedisordersareviewofclinicaltrials AT iulianacostea therapeuticpotentialofpsychedelicsintreatingsubstanceusedisordersareviewofclinicaltrials AT oanaalbai therapeuticpotentialofpsychedelicsintreatingsubstanceusedisordersareviewofclinicaltrials AT lauranussbaum therapeuticpotentialofpsychedelicsintreatingsubstanceusedisordersareviewofclinicaltrials AT adrianacojocaru therapeuticpotentialofpsychedelicsintreatingsubstanceusedisordersareviewofclinicaltrials AT leonardocorsaro therapeuticpotentialofpsychedelicsintreatingsubstanceusedisordersareviewofclinicaltrials AT teodoraanghel therapeuticpotentialofpsychedelicsintreatingsubstanceusedisordersareviewofclinicaltrials |